Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:BLUE NASDAQ:CRSP NASDAQ:DNLI NASDAQ:HALO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.28+1.6%$1.23$0.86▼$3.78$279.98M0.313.33 million shs2.91 million shsBLUEbluebird bio$4.97$4.78$3.20▼$28.60$48.67M0.27447,005 shsN/ACRSPCRISPR Therapeutics$56.80-3.7%$42.52$30.04▼$63.68$4.91B1.821.95 million shs2.88 million shsDNLIDenali Therapeutics$14.52-5.4%$14.25$10.57▼$33.33$2.11B1.331.14 million shs1.69 million shsHALOHalozyme Therapeutics$57.15-0.8%$55.03$42.01▼$70.51$7.04B1.151.76 million shs1.24 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+7.56%-8.57%-11.72%-46.44%BLUEbluebird bio0.00%0.00%0.00%-3.50%-76.11%CRSPCRISPR Therapeutics0.00%+8.91%+37.60%+44.53%+2.23%DNLIDenali Therapeutics0.00%-1.19%-2.75%+14.33%-32.93%HALOHalozyme Therapeutics0.00%+5.74%+4.79%-5.10%+7.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics3.6114 of 5 stars4.51.00.00.03.33.30.6BLUEbluebird bio1.5705 of 5 stars3.10.00.00.00.01.71.3CRSPCRISPR Therapeutics3.2427 of 5 stars4.31.00.00.03.12.50.6DNLIDenali Therapeutics4.6406 of 5 stars4.51.00.04.73.33.30.0HALOHalozyme Therapeutics4.8246 of 5 stars2.14.00.04.42.12.54.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$8.44559.72% UpsideBLUEbluebird bio 2.25Hold$44.60797.38% UpsideCRSPCRISPR Therapeutics 2.53Moderate Buy$71.7526.32% UpsideDNLIDenali Therapeutics 3.06Buy$33.71132.19% UpsideHALOHalozyme Therapeutics 2.17Hold$62.509.36% UpsideCurrent Analyst Ratings BreakdownLatest HALO, BLUE, CRSP, ALLO, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025HALOHalozyme TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$55.007/8/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.005/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/21/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.005/20/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.005/20/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K13,998.72N/AN/A$2.01 per share0.64BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CRSPCRISPR Therapeutics$37.31M131.47N/AN/A$22.64 per share2.51DNLIDenali Therapeutics$330.53M6.38N/AN/A$8.53 per share1.70HALOHalozyme Therapeutics$1.02B6.94$4.65 per share12.28$2.86 per share19.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$3.7615.209.190.3844.76%136.91%26.05%8/5/2025 (Estimated)Latest HALO, BLUE, CRSP, ALLO, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DNLIDenali Therapeutics-$0.73N/AN/AN/AN/AN/A8/6/2025N/AALLOAllogene Therapeutics-$0.28N/AN/AN/AN/AN/A8/5/2025Q2 2025HALOHalozyme Therapeutics$1.22N/AN/AN/A$282.66 millionN/A8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.54N/AN/AN/A$6.44 millionN/A5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/6/2025Q1 2025DNLIDenali Therapeutics-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.719.71BLUEbluebird bio0.370.510.33CRSPCRISPR TherapeuticsN/A15.6415.64DNLIDenali TherapeuticsN/A9.569.56HALOHalozyme Therapeutics3.138.397.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%BLUEbluebird bio87.43%CRSPCRISPR Therapeutics69.20%DNLIDenali Therapeutics92.92%HALOHalozyme Therapeutics97.79%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%BLUEbluebird bio1.40%CRSPCRISPR Therapeutics4.30%DNLIDenali Therapeutics12.50%HALOHalozyme Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310218.73 million189.86 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCRSPCRISPR Therapeutics46086.36 million82.65 millionOptionableDNLIDenali Therapeutics430145.28 million127.12 millionOptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableHALO, BLUE, CRSP, ALLO, and DNLI HeadlinesRecent News About These CompaniesBrown Advisory Inc. Has $2.22 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)2 hours ago | marketbeat.comM&T Bank Corp Reduces Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 12 at 4:51 AM | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Now Covered by Analysts at The Goldman Sachs GroupJuly 12 at 3:11 AM | americanbankingnews.comCaas Capital Management LP Acquires Shares of 4,700 Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 11 at 8:12 AM | marketbeat.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells 20,000 Shares of StockJuly 11 at 6:14 AM | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley Sells 20,000 SharesJuly 10 at 10:31 PM | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Now Covered by The Goldman Sachs GroupJuly 10 at 10:24 AM | marketbeat.comHALO - Halozyme Therapeutics Inc Trailing Returns - MorningstarJuly 9, 2025 | morningstar.comMHarvey Capital Management Inc. Has $9.52 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 9, 2025 | marketbeat.comHere's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 YearsJuly 8, 2025 | benzinga.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Allspring Global Investments Holdings LLCJuly 7, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Hold" by BrokeragesJuly 7, 2025 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Rating of "Hold" from BrokeragesJuly 7, 2025 | marketbeat.comHALO - Halozyme Therapeutics Inc Financials - MorningstarJuly 5, 2025 | morningstar.comMMoody Aldrich Partners LLC Has $6.17 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 4, 2025 | marketbeat.comHALO - Halozyme Therapeutics Inc Valuation - MorningstarJuly 3, 2025 | morningstar.comMWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-TermJuly 3, 2025 | zacks.comMeritage Portfolio Management Buys Shares of 101,651 Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 3, 2025 | marketbeat.comNovem Group Acquires 4,821 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 3, 2025 | marketbeat.comOppenheimer & Co. Inc. Takes $625,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 1, 2025 | marketbeat.comHalozyme Therapeutics Added to Russell 1000® IndexJune 30, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAddition by Subtraction: Intel’s New Strategy Energizes InvestorsBy Jeffrey Neal Johnson | June 27, 2025View Addition by Subtraction: Intel’s New Strategy Energizes InvestorsDon’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBy Chris Markoch | July 8, 2025View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonThe Apple Comeback Will Be Better Than the SetbackBy Gabriel Osorio-Mazilli | July 4, 2025View The Apple Comeback Will Be Better Than the SetbackOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesHSAs for Gym Memberships? These 3 Fitness Stocks Could SoarBy Chris Markoch | June 24, 2025View HSAs for Gym Memberships? These 3 Fitness Stocks Could SoarHALO, BLUE, CRSP, ALLO, and DNLI Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.28 +0.02 (+1.59%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.29 +0.01 (+0.78%) As of 07/11/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.bluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$56.80 -2.20 (-3.73%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$56.40 -0.39 (-0.70%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Denali Therapeutics NASDAQ:DNLI$14.52 -0.83 (-5.41%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$14.52 0.00 (-0.03%) As of 07/11/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Halozyme Therapeutics NASDAQ:HALO$57.15 -0.48 (-0.83%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$57.16 +0.01 (+0.02%) As of 07/11/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
